These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 26648342

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G, Maffioli P.
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64. Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation.
    Yamamoto E, Nakamura T, Kataoka K, Tokutomi Y, Dong YF, Fukuda M, Nako H, Yasuda O, Ogawa H, Kim-Mitsuyama S.
    Biochem Biophys Res Commun; 2010 Dec 17; 403(3-4):258-63. PubMed ID: 21059340
    [Abstract] [Full Text] [Related]

  • 65. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
    Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC.
    Am J Cardiovasc Drugs; 2006 Dec 17; 6(4):231-42. PubMed ID: 16913824
    [Abstract] [Full Text] [Related]

  • 66. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
    Iwai M, Kanno H, Inaba S, Senba I, Sone H, Nakaoka H, Horiuchi M.
    Am J Hypertens; 2011 Feb 17; 24(2):169-74. PubMed ID: 20847723
    [Abstract] [Full Text] [Related]

  • 67. Protection of blood-brain barrier breakdown by nifedipine in adrenaline-induced acute hypertension.
    Nukhet Turkel A, Ziya Ziylan Y.
    Int J Neurosci; 2004 Apr 17; 114(4):517-28. PubMed ID: 15195355
    [Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70. Salubrious effects of ulinastatin and quercetin alone or in combination in endothelial dysfunction and vascular dementia.
    Sharma P, Gaur N, Jayant S, Sharma BM, Singh B, Kharkwal H, Sharma B.
    Pharmacol Rep; 2022 Jun 17; 74(3):481-492. PubMed ID: 35396697
    [Abstract] [Full Text] [Related]

  • 71. Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice.
    Almasi-Nasrabadi M, Javadi-Paydar M, Mahdavian S, Babaei R, Sharifian M, Norouzi A, Dehpour AR.
    Behav Brain Res; 2012 May 16; 231(1):138-45. PubMed ID: 22440233
    [Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats.
    Ito K, Shimada J, Kato D, Toda S, Takagi T, Naito Y, Yoshikawa T, Kitamura N.
    Eur J Cardiothorac Surg; 2004 Apr 16; 25(4):530-6. PubMed ID: 15037267
    [Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Lycopene attenuates diabetes-associated cognitive decline in rats.
    Kuhad A, Sethi R, Chopra K.
    Life Sci; 2008 Jul 18; 83(3-4):128-34. PubMed ID: 18585396
    [Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Hybrid drug combination: Anti-diabetic treatment of type 2 diabetic Wistar rats with combination of ellagic acid and pioglitazone.
    Nankar RP, Doble M.
    Phytomedicine; 2017 Dec 15; 37():4-9. PubMed ID: 29103827
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.